Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Spatial Genomics, Transcriptomics and Proteomics Solutions Market - Distribution by Type of Solution, Type of Sample, End Users, Research Areas, and Key Geographical Regions: Industry Trends and Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
The report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the spatial omics solutions market. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this domain.
Since the discovery of the first human genetic map in 1987, the field of omics-based analysis has evolved significantly. Researchers have focused their efforts from decoding the primary sequence of genes to analyzing the location and interaction of cell types, and biomarkers (primarily, DNA, RNA and proteins), through a process known as spatial phenotyping.
The traditional molecular profiling analytical techniques, such as microarrays quantitative polymerase chain reaction (qPCR), flow cytometry, mass spectrometry, immunohistochemistry and enzyme linked immunosorbent (ELISA) assay, though widely adopted, are known to dissociate the tissue samples, thereby causing loss of critical spatial multi-omics information across the genome, transcriptome, and proteome.
This unmet need in the life sciences research market has prompted innovators to amalgamate cell imaging and molecular profiling techniques to enable visualization, as well as high-throughput quantification of the cells and biomarkers within the tissue samples.
These solutions (that include platforms, along with affiliated reagents and software applications) enable the researchers to further advance and scale their research, by offering a better understanding of the disease morphology, discover novel biomarkers and develop precision therapies. Additionally, these spatial phenotyping platforms can be seamlessly integrated with the current NGS-workflows.
Therefore, the adoption of these novel devices to scale research from discovery to translational and clinical phases, is on the rise. In fact, according to a recent survey, approximately 44% of respondents expressed their intent to purchase a spatial profiling platform. In the same year, a research study, published in JAMA Oncology, emphasized the superiority of spatial phenotyping methods for the biomarker analysis in patients suffering from immuno-oncological diseases. Further, Nature Methods dubbed Spatial Transcriptomics as "Method of the Year" for 2020.
In order to capitalize the growing opportunity within this niche market, the developers of spatial-omics solutions are engaged in efforts to improve the penetration of their proprietary technologies, within the diverse client base, including academic research centers, research institutes and biopharma companies.
As a result, they are engaged in incorporating advanced features to their devices, including machine learning-based image analysis, automated sample processing, high-multiplexing, and biomarker-specific gene panels (including those associated with SARS-CoV-2). At the same time, the cost of running these complex tests has dramatically decreased in recent years; the spatial analysis of high-plex stained panels now costs USD 1,000 per slide, which is similar to the cost of whole genome sequencing by NGS.
Further, these instruments are designed to be capable of processing formalin-fixed paraffin embedded (FFPE) tissue sample. This feature is important because nearly 80% of the translational research studies, that use tissue samples, are dependent on the aforementioned sample type.
Few players have also introduced customized access programs for biopharmaceutical players, enabling them to leverage spatial omics technologies, for the purpose of guiding their drug development programs. Driven by the growing adoption and continuous innovation of spatial biology solutions, we are led to believe that the opportunity for spatial profiling solution providers is likely to witness a sustained growth over the coming years.
Scope of the Report
One of the key objectives of the report was to estimate the existing market size and the potential future growth opportunity associated with spatial omics solutions providers in the mid to long term. We have developed informed estimates on the evolution of the market for the period 2022-2035.
The report features detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
Key Players
Spatial Omics Analysis Solution Providers: North America
Spatial Omics Analysis Solution Providers: Europe
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. SPATIAL OMICS SOLUTIONS: MARKET LANDSCAPE
5. SPATIAL OMICS SOLUTIONS: PRODUCT COMPETITIVENESS ANALYSIS
6. SPATIAL OMICS SOLUTIONS: COMPANY PROFILES
7. PARTNERSHIPS AND COLLABORATIONS
8. PATENT ANALYSIS
9. PUBLICATION ANALYSIS
10. CASE STUDY ON POTENTIAL CLIENTS OF SPATIAL OMICS SOLUTION PROVIDERS
11. CASE STUDY ON SEQUENCING TECHNOLOGIES
12. SPATIAL OMICS SOLUTION PROVIDERS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
13. EXECUTIVE INSIGHTS
14. CONCLUDING REMARKS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/v25kvt